Medicines & Healthcare products Regulatory Agency

MHRA

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Ms Heather House
UNIVERSITY OF OXFORD
CLINICAL TRIALS AND RESEARCH GOVERNANCE, JOINT RESEARCH OFFICE,
1ST FLOOR, BOUNDARY BROOK HOUSE, CHURCHILL DRIVE, HEADINGTON
OXFORD
OX3 7LQ
UNITED KINGDOM

16/03/2020

Dear Ms Heather House

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference	CTA 21584/0423/001-0001
Eudract Number	2020-001113-21
Product	Lopinavir/ritonavir, Dexamethasone, Interferon beta-1a
Protocol number	NDPHRECOVERY

ACKNOWLEDGEMENT

Thank you for your request for a clinical trial authorisation (CTA), received on 13/03/2020.

The information you have provided to support your request is complete and therefore your request is valid.

Your request will be assessed and you will be notified of the Licensing Authority's decision in accordance with the timescales set out in Regulations 18-20.

Yours sincerely,

Submissions
MHRA